{"id":"https://openalex.org/W1998298073","doi":"https://doi.org/10.1097/00004850-200111000-00005","title":"Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression","display_name":"Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression","publication_year":2001,"publication_date":"2001-11-01","ids":{"openalex":"https://openalex.org/W1998298073","doi":"https://doi.org/10.1097/00004850-200111000-00005","mag":"1998298073","pmid":"https://pubmed.ncbi.nlm.nih.gov/11712623"},"language":"en","primary_location":{"id":"doi:10.1097/00004850-200111000-00005","doi":"https://doi.org/10.1097/00004850-200111000-00005","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004850-200111000-00005","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112066093","display_name":"John P. Feighner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405274856","display_name":"SNBL INA Ltd. (Japan)","ror":"https://ror.org/02gav4q94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405274856"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"J. P. Feighner","raw_affiliation_strings":["Innapharma Inc., Park Ridge, NJ 07656, USA","Innapharma Inc., Park Ridge, NJ, USA","Received 20 March 2001","accepted 4 September 2001","e-mail: [email\u00a0protected]","fax:+1 201 505 1501"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Innapharma Inc., Park Ridge, NJ 07656, USA","institution_ids":["https://openalex.org/I4405274856"]},{"raw_affiliation_string":"Innapharma Inc., Park Ridge, NJ, USA","institution_ids":[]},{"raw_affiliation_string":"Received 20 March 2001","institution_ids":[]},{"raw_affiliation_string":"accepted 4 September 2001","institution_ids":[]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax:+1 201 505 1501","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005439656","display_name":"Rudolph H. Ehrensing","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. H. Ehrensing","raw_affiliation_strings":["to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","Innapharma Inc., Park Ridge, NJ, USA","Received 20 March 2001","accepted 4 September 2001","e-mail: [email\u00a0protected]","fax:+1 201 505 1501"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"Innapharma Inc., Park Ridge, NJ, USA","institution_ids":[]},{"raw_affiliation_string":"Received 20 March 2001","institution_ids":[]},{"raw_affiliation_string":"accepted 4 September 2001","institution_ids":[]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax:+1 201 505 1501","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032152107","display_name":"Abba J. Kastin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. J. Kastin","raw_affiliation_strings":["to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","Innapharma Inc., Park Ridge, NJ, USA","Received 20 March 2001","accepted 4 September 2001","e-mail: [email\u00a0protected]","fax:+1 201 505 1501"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"Innapharma Inc., Park Ridge, NJ, USA","institution_ids":[]},{"raw_affiliation_string":"Received 20 March 2001","institution_ids":[]},{"raw_affiliation_string":"accepted 4 September 2001","institution_ids":[]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax:+1 201 505 1501","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069647453","display_name":"Arpankumar Patel","orcid":"https://orcid.org/0000-0001-7416-2211","observed_orcids":["https://orcid.org/0000-0001-7416-2211"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Patel","raw_affiliation_strings":["to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","Innapharma Inc., Park Ridge, NJ, USA","Received 20 March 2001","accepted 4 September 2001","e-mail: [email\u00a0protected]","fax:+1 201 505 1501"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"Innapharma Inc., Park Ridge, NJ, USA","institution_ids":[]},{"raw_affiliation_string":"Received 20 March 2001","institution_ids":[]},{"raw_affiliation_string":"accepted 4 September 2001","institution_ids":[]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax:+1 201 505 1501","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087508888","display_name":"Lev Sverdlov","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Sverdlov","raw_affiliation_strings":["to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","Innapharma Inc., Park Ridge, NJ, USA","Received 20 March 2001","accepted 4 September 2001","e-mail: [email\u00a0protected]","fax:+1 201 505 1501"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"Innapharma Inc., Park Ridge, NJ, USA","institution_ids":[]},{"raw_affiliation_string":"Received 20 March 2001","institution_ids":[]},{"raw_affiliation_string":"accepted 4 September 2001","institution_ids":[]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax:+1 201 505 1501","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023035240","display_name":"Joseph Hlavka","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Hlavka","raw_affiliation_strings":["to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","Innapharma Inc., Park Ridge, NJ, USA","Received 20 March 2001","accepted 4 September 2001","e-mail: [email\u00a0protected]","fax:+1 201 505 1501"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"Innapharma Inc., Park Ridge, NJ, USA","institution_ids":[]},{"raw_affiliation_string":"Received 20 March 2001","institution_ids":[]},{"raw_affiliation_string":"accepted 4 September 2001","institution_ids":[]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax:+1 201 505 1501","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090514851","display_name":"H. Abajian","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. B. Abajian","raw_affiliation_strings":["to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","Innapharma Inc., Park Ridge, NJ, USA","Received 20 March 2001","accepted 4 September 2001","e-mail: [email\u00a0protected]","fax:+1 201 505 1501"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"Innapharma Inc., Park Ridge, NJ, USA","institution_ids":[]},{"raw_affiliation_string":"Received 20 March 2001","institution_ids":[]},{"raw_affiliation_string":"accepted 4 September 2001","institution_ids":[]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax:+1 201 505 1501","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082393967","display_name":"John F. Noble","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. F. Noble","raw_affiliation_strings":["to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","Innapharma Inc., Park Ridge, NJ, USA","Received 20 March 2001","accepted 4 September 2001","e-mail: [email\u00a0protected]","fax:+1 201 505 1501"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"Innapharma Inc., Park Ridge, NJ, USA","institution_ids":[]},{"raw_affiliation_string":"Received 20 March 2001","institution_ids":[]},{"raw_affiliation_string":"accepted 4 September 2001","institution_ids":[]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax:+1 201 505 1501","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112482908","display_name":"Gabriela Nicolau","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"G. Nicolau","raw_affiliation_strings":["to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","Innapharma Inc., Park Ridge, NJ, USA","Received 20 March 2001","accepted 4 September 2001","e-mail: [email\u00a0protected]","fax:+1 201 505 1501"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"to Gabriela Nicolau, Innapharma, Inc., 1 Maynard Drive, Suite 205, Park Ridge, NJ 07656, USA Tel:+1 201 505 1300; fax:+1 201 505 1501; e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"Innapharma Inc., Park Ridge, NJ, USA","institution_ids":[]},{"raw_affiliation_string":"Received 20 March 2001","institution_ids":[]},{"raw_affiliation_string":"accepted 4 September 2001","institution_ids":[]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax:+1 201 505 1501","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5112482908"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.5545,"has_fulltext":false,"cited_by_count":18,"citation_normalized_percentile":{"value":0.81991257,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"16","issue":"6","first_page":"345","last_page":"352"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11337","display_name":"Tryptophan and brain disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2803","display_name":"Biological Psychiatry"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13118","display_name":"Psychological Treatments and Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.8100000023841858},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.7799999713897705},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9079999923706055},{"id":"https://openalex.org/keywords/plasma-drug-concentration","display_name":"plasma drug concentration","score":0.6869999766349792},{"id":"https://openalex.org/keywords/pharmacodynamic-response","display_name":"pharmacodynamic response","score":0.6940000057220459},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.8889999985694885},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.5440000295639038},{"id":"https://openalex.org/keywords/onset-of-action","display_name":"onset of action","score":0.8220000267028809},{"id":"https://openalex.org/keywords/outpatients","display_name":"outpatients","score":0.8040000200271606}],"concepts":[{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.8315479755401611},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.738358199596405},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.6383424997329712},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6311386227607727},{"id":"https://openalex.org/C2776867660","wikidata":"https://www.wikidata.org/wiki/Q1814941","display_name":"Depression (economics)","level":2,"score":0.6272263526916504},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5985115766525269},{"id":"https://openalex.org/C83849319","wikidata":"https://www.wikidata.org/wiki/Q7295720","display_name":"Rating scale","level":2,"score":0.5674614906311035},{"id":"https://openalex.org/C2776000289","wikidata":"https://www.wikidata.org/wiki/Q5133761","display_name":"Clinical Global Impression","level":4,"score":0.5672447085380554},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5610581636428833},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5569884181022644},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5397030711174011},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5072154998779297},{"id":"https://openalex.org/C2776466505","wikidata":"https://www.wikidata.org/wiki/Q385555","display_name":"Hamilton Rating Scale for Depression","level":4,"score":0.4496581256389618},{"id":"https://openalex.org/C46821324","wikidata":"https://www.wikidata.org/wiki/Q7094540","display_name":"Onset of action","level":2,"score":0.42813020944595337},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3922479450702667},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.2654880881309509},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.1989782750606537},{"id":"https://openalex.org/C2779144063","wikidata":"https://www.wikidata.org/wiki/Q338924","display_name":"Amygdala","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.0},{"id":"https://openalex.org/C138496976","wikidata":"https://www.wikidata.org/wiki/Q175002","display_name":"Developmental psychology","level":1,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C139719470","wikidata":"https://www.wikidata.org/wiki/Q39680","display_name":"Macroeconomics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003866","descriptor_name":"Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003866","descriptor_name":"Depressive Disorder","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010045","descriptor_name":"Outpatients","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00004850-200111000-00005","doi":"https://doi.org/10.1097/00004850-200111000-00005","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004850-200111000-00005","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:11712623","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11712623","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International clinical psychopharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":9,"referenced_works":["https://openalex.org/W1975927660","https://openalex.org/W2063991458","https://openalex.org/W2074401012","https://openalex.org/W2077997956","https://openalex.org/W2083435114","https://openalex.org/W2090762833","https://openalex.org/W2110361936","https://openalex.org/W2124297789","https://openalex.org/W2430482639"],"related_works":["https://openalex.org/W2110361936","https://openalex.org/W2095718235","https://openalex.org/W2020879838","https://openalex.org/W1970100430","https://openalex.org/W2003537831","https://openalex.org/W2363548892","https://openalex.org/W2052885793","https://openalex.org/W2170790660","https://openalex.org/W2109334244","https://openalex.org/W2061692607"],"abstract_inverted_index":{"This":[0],"study":[1],"was":[2,34,85,121,177,186],"designed":[3],"to":[4,27,129],"determine":[5],"the":[6,12,47,88,109,152,167],"safety,":[7],"efficacy":[8,195],"and":[9,71,102,127,194,212],"pharmacokinetics":[10],"of":[11,41,81,108,135,175,210],"antidepressant":[13,206],"netamiftide":[14,84,136],"(previously":[15],"designated":[16],"name:":[17],"INN":[18],"00835)":[19],"after":[20,145,182,192],"5":[21,61,67],"or":[22,157],"10":[23,55,74],"daily":[24],"doses":[25],"administered":[26,35],"patients":[28,110],"diagnosed":[29],"with":[30,57,63,69,76,83,154,169,207,213],"major":[31],"depression.":[32],"Netamiftide":[33,202],"subcutaneously":[36],"at":[37,142,188],"a":[38,198,204],"fixed":[39],"dose":[40],"18":[42],"mg/patient":[43],"per":[44],"day.":[45],"Of":[46],"55":[48],"enrolled":[49],"patients,":[50],"22":[51,72],"were":[52,140,148],"dosed":[53],"for":[54,60,73],"days":[56,62,68,75],"drug,":[58],"11":[59],"drug":[64,125],"followed":[65],"by":[66,87],"placebo":[70,77],"only.":[78],"The":[79],"effect":[80,185],"treatment":[82,193],"evaluated":[86],"following":[89],"psychometric":[90],"tests:":[91],"Hamilton":[92],"Depression":[93,96,101],"Rating,":[94],"Montgomery-Asberg":[95],"Rating":[97],"Scale,":[98],"Carroll":[99],"Self-Rating":[100],"Clinical":[103],"Global":[104],"Impression":[105],"scales.":[106],"None":[107],"experienced":[111],"significant":[112],"adverse":[113],"effects.":[114],"A":[115],"pharmacodynamic":[116],"correlation":[117],"(P":[118],"<":[119,171],"0.05)":[120],"found":[122],"between":[123],"plasma":[124,132],"concentrations":[126,133],"response":[128],"treatment.":[130],"Highest":[131],"(Cmax)":[134],"averaging":[137],"45.7":[138,159,172],"ng/ml":[139,160],"observed":[141,178,187],"0.25":[143],"h":[144,181],"dosing.":[146],"There":[147],"89%":[149],"responders":[150],"in":[151,166],"group":[153,168],"Cmax":[155,170],">":[156],"=":[158],"(minimum":[161],"therapeutic":[162],"concentration)":[163],"versus":[164],"40%":[165],"ng/ml.":[173],"Onset":[174],"action":[176,211],"within":[179],"48":[180],"treatment,":[183],"peak":[184],"approximately":[189],"1":[190],"week":[191],"lasted":[196],"during":[197],"4-week":[199],"follow-up":[200],"period.":[201],"is":[203],"promising":[205],"rapid":[208],"onset":[209],"an":[214],"excellent":[215],"safety":[216],"profile.":[217]},"counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2016-06-24T00:00:00"}